Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FSD Pharma Inc C.HUGE

Alternate Symbol(s):  HUGE

Healthcare Cannabis
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is... see more

Recent & Breaking News (CSE:HUGE)

FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome

Business Wire September 6, 2022

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

Business Wire July 13, 2022

FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates

Business Wire June 27, 2022

FSD Pharma Files Investigational New Drug Application ("IND") with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates

Business Wire May 31, 2022

FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs

Business Wire May 24, 2022

FSD Pharma closes $16 million-plus sale of non-core assets

Stockhouse Editorial May 11, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

Business Wire May 10, 2022

FSD Pharma Announces Dismissal of Derivative Complaint

Business Wire May 6, 2022

FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates

Business Wire May 2, 2022

FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board

Business Wire April 21, 2022

FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari

Business Wire April 8, 2022

FSD Pharma Issues Corporate Updates

Business Wire April 6, 2022

FSD Pharma Announces Filing of Year-End 2021 Results

Business Wire March 31, 2022

The StockTalk Cannabis Report: Mar 18, 2022

Dave Jackson March 18, 2022

FSD Pharma announces Executive Informational Overview Report

Stockhouse Editorial March 16, 2022

FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC

Business Wire March 15, 2022

FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000

Business Wire February 25, 2022

FSD Pharma Announces Launch of New Corporate Website

Business Wire January 20, 2022

FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada

Business Wire January 18, 2022

The StockTalk Cannabis Report: Jan 7, 2022

Dave Jackson January 7, 2022